PDCD1 and metastatic melanoma: In this study, we verified that baseline FT3, baseline A-TPO, LDH, and M stage (presence/absence of liver and brain metastases) were the independent prognostic factors of OS in patients with metastatic melanoma treated with PD-1 antibody, through the univariate and multivariate analyses.